VETC, Prognostic and Predictive Value in Renal Cell Carcinoma and Adrenal Carcinoma

Renal Cell Carcinoma Clinical Trial

Official title:

Vessels Encapsulating Tumor Clusters (VETC), Prognostic and Predictive Value in Renal Cell Carcinoma and Adrenal Gland Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04666220
• Other study ID #: Predictive VETC
• Status: Recruiting
• Start date: January 2, 2021
• Est. completion date: May 2021

Study information

• Verified date: February 2021
• Source: Humanitas Clinical and Research Center
• Contact: Salvatore L Renne, MD
• Phone: +39028224 7743
• Email: salvatore.renne[@]hunimed.eu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Metastasis is the main cause of death in cancer patients and often epithelial-to-mesenchymal transition (EMT) is advocated as the basic mechanism. Recently Fang and colleagues described an EMT-independent process of metastasis in hepatocellular carcinoma (HCC): endothelium covers small cluster of tumor cells allowing tumor dissemination. This process of angiogenesis, named VETC (vessels that encapsulate tumor clusters) in HCC literature, has been described under different names in other cancer types. Furthermore, the investigators confirmed the negative impact of VETC on patients' prognosis on a large multicenter cohort of HCCs. Moreover, Fang et al demonstrated that patients affected by VETC-positive HCC benefit more from sorafenib therapy. Interestingly, this type of angiogenesis was also found in renal cell carcinoma, adrenal gland pheochromocytoma, thyroid follicular carcinoma and alveolar soft part sarcoma (ASPS) and associated to prognosis. Moreover, the distinction between benign and malignant neoplasms of the adrenal gland is a complex matter, being the established criteria still lacking a strong reproducibility.

Several tyrosine kinase inhibitors are available for different cancer types; among them, HCC, RCC, ASPS, and TC may benefit from the so-called antiangiogenic tyrosine kinase inhibitors (aTKI) (such as sunitinib, sorafenib, pazopanib). A general (histotype-independent) validation of the prognostic role of VETC is missing. Moreover, inhibitors of tyrosine-kinase vascular endothelial growth factor receptors (VEGFR-TKI), represent an effective treatment for different cancer types, but predictive markers are still needed. In addition, novel systemic immunotherapy agents are being approved in many cancer types, as alternative to angiogenesis inhibitors. A broader frame including metastatic mechanisms, tumor microenvironment (TME, i.e. angiogenesis and immune infiltrate) and treatment response could answer to several needs currently unmet. Bayesian networks and causal models can be employed to effectively draw conclusions from retrospective data.

The aim of the present study is to investigate in patients with RCC and adrenal carcinoma (AC) the VETC-expression on tumor tissue, correlating the results with clinical data, patients characteristics, and outcome.

Description:

Background and introduction

Metastasis is the main cause of death in cancer patients and often epithelial-to-mesenchymal transition (EMT) is advocated as the basic mechanism, although some limitations have been identified [1,2] Recently Fang and colleagues described an EMT-independent process of metastasis in hepatocellular carcinoma (HCC): endothelium (highlighted by CD34 immunohistochemistry) covers small cluster of tumor cells allowing tumor dissemination [3]. This process of angiogenesis, named VETC (vessels that encapsulate tumor clusters) in HCC literature, has been described under different names in other cancer types [4]. Furthermore, the investigators confirmed the negative impact of VETC on patients' prognosis on a large multicenter cohort of HCCs [5]. Moreover, Fang et al demonstrated that patients affected by VETC-positive HCC benefit more from sorafenib therapy [6]. Interestingly, this type of angiogenesis was also found in renal cell carcinoma, adrenal gland pheochromocytoma, thyroid follicular carcinoma and alveolar soft part sarcoma (ASPS) and associated to prognosis [7-10, 34,35]. Moreover, the distinction between benign and malignant neoplasms of the adrenal gland is a complex matter, being the established criteria still lacking a strong reproducibility [36].

Several tyrosine kinase inhibitors are available for different cancer types; among them, HCC, RCC, ASPS, and TC may benefit from the so-called antiangiogenic tyrosine kinase inhibitors (aTKI) (such as sunitinib, sorafenib, pazopanib) [11-14].

Rationale of the study A general (histotype-independent) validation of the prognostic role of VETC is missing. Moreover, inhibitors of tyrosine-kinase vascular endothelial growth factor receptors (VEGFR-TKI), represent an effective treatment for different cancer types, but predictive markers are still needed. Moreover, novel systemic immunotherapy agents are being approved in many cancer types, as alternative to angiogenesis inhibitors. A broader frame including metastatic mechanisms, tumor microenvironment (TME, i.e. angiogenesis and immune infiltrate) and treatment response could answer to several needs currently unmet. Bayesian networks and causal models can be employed to effectively draw conclusions from retrospective data.

Objectives of the study General objectives

1. The systematic investigation of VETC in RCC and AC in order to depict the impact of this phenomenon.

2. To explore the possible role of TME and in particular of VETC in predicting a more beneficial response to VEGFR-TKIs, providing a new tool in guiding the therapeutic choice.

Study Design The study is monocentric, observational, and it will be performed on clinical and histological data collected in the course of study.

For all series, clinical and epidemiological features will be recorded, all available histological slides will be reviewed and, on the primary tumor slides, histological characteristics will be re-assessed.

Whenever multiple samples of tumors would be present, those having the tumor-surrounding tissue interface will be selected and stained with CD34 antibody.

VETC will be evaluated independently by, at least, two pathologists, blinded to clinical data. VETC will be recorded as positive or negative, being VETC defined as CD34 unequivocal immunoreactivity of a continuous lining of endothelial cells around tumor clusters. VETC will be considered alternative to the common capillary pattern, consisting in small circular or linear blood vessels.

Statistical considerations The project plans to collect data of 100 of patients who underwent surgery for RCC at our institution between 2005 and 2007 for the evaluation of VETC impact on prognosis, and data of 60 patients who received sunitinib or pazopanib as first-line treatment for RCC at our center to explore if patients with VETC vascular phenotype would benefit more from the treatment with TKIs. Furthermore, the investigators will collect data of 20 patients who underwent surgery for AC at our Institution between 2000 and 2018.

Bayesian Analysis Directed acyclic graphs will be constructed with available scientific information; adjustment sets and conditional independencies will be calculated [15-17]. Prior predictive simulations, when relevant, will be deployed to regularize the prior and reduce overfitting. Continuous variables will be standardized to facilitate sampling. Models will be fit using Stan (a probabilistic programming language) and R [18,19]. Stan runs a No U-Turn sampler, an extension to Hamiltonian Monte Carlo (HMC) sampling, which is itself a form of Markov Chain Monte Carlo [20-22]. Four chains for 4000 iterations, or 8000 whenever the bulk effective sample size will be low, will be generated. The final 2000 (or 4000) iterations of each chain converge as indicated by post-modeling diagnostics such as the number of effective Gelman-Rubin R ̂.[23] A satisfactory posterior predictive model performance will be ensured before using sample means (for estimates) and sample quantiles (for compatibility intervals (CI)) [23,24]. CI will be calculated as 89% of the highest posterior density interval (HDPI) [23]. Whenever more clusters of data would be present, the investigators will use varying effects multilevel (hierarchical) models [25]. To limit divergent transitions, the investigators will reparameterize the models with a non-centered equivalent form [26] Predictive accuracy will be measured trough widely applicable information criteria (WAIC) [27].

Withdrawal of subjects Missing data will be treated modeling the missingness process. [28-29]

Forms and procedures for collecting data and data managing To each subject will be assigned a sequential identification number. For each subject data will be collected in a case report form (CRF). CRF will include SIN, name, sex, date of birth, date of primary surgery, side , size, histotype, relevant grading, necrosis, lymphovascular invasion , R , stage, date of TKI therapy, date of disease progression, prognostic scores (IMDC score [30], MSKCC score [31]), Karnofsky score [32], first-last line data (type, dates of beginning and end, best response, progression date), last follow-up status, last contact, death, VETC. All data will be registered in Microsoft Excel spreadsheet format. Data are collected by the data manager and database base will be locked with a password. Spaces will be filled with "NA" whenever a characteristic was not explored or an item is not applicable to the individual case.

For AC, CRF will include SIN, name, sex, date of birth, date of primary surgery, side, size, and prognostic criteria for malignancy based on Weiss Classification mod [33].

Ethical considerations Patient protection The responsible investigator will ensure that this study will be conducted in agreement with either the Declaration of Helsinki (Tokyo, Venice, Hong Kong and Somerset West amendments) or the laws and regulations of the country.

The protocol has been written, and the study will be conducted according to the institutional (ICH) Guideline for Good Clinical Practice The protocol and its annexes were subject to review and approval by the competent Independent Ethics Committee(s) ("IEC").

Subject identification - Personal Data protection All records identifying the subject must be kept confidential and, to the extent permitted by the applicable laws and/or regulations, not be made publicly available. The name of the patient will not be asked for nor recorded at the Data Center. A sequential identification number will be automatically attributed to each patient registered in the study. This number will identify the patient and must be included on all case report forms. In order to avoid identification errors, patient initials and date of birth will also be reported on the case report forms.

Any and all patient information or documentation pertaining to a clinical trial, to the extent permitting, through a "key" kept anywhere, regardless of whether such key is supplied along with the information or documentation or not, must be considered as containing sensitive personal data of the patient, and is therefore subjected to the provisions of applicable data protection ("privacy") regulations. Breach of such regulations may result in administrative or even criminal sanctions.

Patient information or documentation may be considered "anonymous", and as such not subject to privacy regulations, only when no key whatsoever, permitting the identification of the patient, is any longer available.

Informed consent All patients will be informed of the aims of the study. They will be informed as to the strict confidentiality of their patient data, but that their medical records may be reviewed for study purposes by authorized individuals other than their treating physician.It will be emphasized that the participation is voluntary and that the patient is allowed to refuse further participation in the protocol whenever he/she wants. This will not prejudice the patient's subsequent care. Documented informed consent must be obtained for all patients included in the study before they are registered at the Data Center. This must be done in accordance with the national and local regulatory requirements. For European Union member states, the informed consent procedure must conform to the ICH guidelines on Good Clinical Practice. This implies that "the written informed consent form should be signed and personally dated by the patient or by the patient's legally acceptable representative".

Conflict of Interest Any investigator and/or research staff member who has a conflict of interest with this study (such as patent ownership, royalties, or financial gain greater than the minimum allowable by their institution) must fully disclose the nature of the conflict of interest.

Data ownership According to the ICH Guidelines on Good Clinical Practice the sponsor of a study (the Institution, should the investigator or study coordinators act as sponsor in the performance of her/his institutional duties under the employment or collaboration agreement with Humanitas) is the owner of the data resulting therefrom. All centers and investigators participating in the study should be made aware of such circumstance and invited not to disseminate information or data without the Institution's prior express consent.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 180
• Est. completion date: May 2021
• Est. primary completion date: February 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Histological diagnosis of Renal Cell Carcinoma;

2. Histological diagnosis of Carcinoma of the adrenal gland;

3. Availability of histological material;

4. For the evaluation of the prognostic role: no systemic treatment with TKI administered before surgery.

Exclusion Criteria:

1. Unavailable histological material;

2. For RCC: histological diagnosis different from Clear Cell histotype.

Related Conditions & MeSH terms

• Adrenal Carcinoma
• Adrenocortical Carcinoma
• Carcinoma
• Carcinoma, Renal Cell
• Renal Cell Carcinoma

Intervention

Other:
• VETC evaluation
We will evaluate VETC presence on tissue specimens

Locations

Country	Name	City	State
Italy	Humanitas Clinical and Research Hospital	Rozzano	MI

Sponsors (1)

Lead Sponsor	Collaborator
Humanitas Clinical and Research Center

Country where clinical trial is conducted

Italy, 

References & Publications (36)

Aubert S, Wacrenier A, Leroy X, Devos P, Carnaille B, Proye C, Wemeau JL, Lecomte-Houcke M, Leteurtre E. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol. 2002 Dec;26(12):1612-9. — View Citation

Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ; DECISION investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014 Jul 26;384(9940):319-28. doi: 10.1016/S0140-6736(14)60421-9. Epub 2014 Apr 24. — View Citation

Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011 May 19;473(7347):298-307. doi: 10.1038/nature10144. Review. — View Citation

Carpenter, B. et al. Stan : A Probabilistic Programming Language. J. Stat. Softw. 76, (2017).

Duane, S., Kennedy, A. D., Pendleton, B. J. & Roweth, D. Hybrid Monte Carlo. Phys. Lett. B 195, 216-222 (1987).

Edeline J, Mottier S, Vigneau C, Jouan F, Perrin C, Zerrouki S, Fergelot P, Patard JJ, Rioux-Leclercq N. Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma. Hum Pathol. 2012 Nov;43(11):1982-90. doi: 10.1016/j.humpath.2012.01.023. Epub 2012 May 22. — View Citation

Fang JH, Xu L, Shang LR, Pan CZ, Ding J, Tang YQ, Liu H, Liu CX, Zheng JL, Zhang YJ, Zhou ZG, Xu J, Zheng L, Chen MS, Zhuang SM. Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma. Hepatology. 2019 Sep;70(3):824-839. doi: 10.1002/hep.30366. Epub 2019 Mar 15. — View Citation

Fang JH, Zhou HC, Zhang C, Shang LR, Zhang L, Xu J, Zheng L, Yuan Y, Guo RP, Jia WH, Yun JP, Chen MS, Zhang Y, Zhuang SM. A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner. Hepatology. 2015 Aug;62(2):452-65. doi: 10.1002/hep.27760. Epub 2015 Apr 22. — View Citation

Favier J, Plouin PF, Corvol P, Gasc JM. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol. 2002 Oct;161(4):1235-46. — View Citation

Gelman, A. Discussion paper analysis of variance - Why it is more important than ever. Ann. Stat. 33, 1-53 (2005).

Gelman, A. et al. Bayesian data analysis. (CRC press, 2013).

Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009 Dec 1;27(34):5794-9. doi: 10.1200/JCO.2008.21.4809. Epub 2009 Oct 13. — View Citation

Hoffman, M. D. & Gelman, A. The no-U-turn sampler: Adaptively setting path lengths in Hamiltonian Monte Carlo. J. Mach. Learn. Res. 15, 1593-1623 (2014).

Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009 Jun;119(6):1420-8. doi: 10.1172/JCI39104. Review. Erratum in: J Clin Invest. 2010 May 3;120(5):1786. — View Citation

Karnofsky DA Burchenal JH. (1949). 'The Clinical Evaluation of Chemotherapeutic Agents in Cancer.' In: MacLeod CM (Ed), Evaluation of Chemotherapeutic Agents. Columbia Univ Press. Page 196.

Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol. 2009 Jun;40(6):757-68. doi: 10.1016/j.humpath.2009.03.010. — View Citation

Ledford H. Cancer theory faces doubts. Nature. 2011 Apr 21;472(7343):273. doi: 10.1038/472273a. — View Citation

Little, R. J. A. & Rubin, D. B. Statistical Analysis with Missing Data. (Wiley, 2019).

López JI, Erramuzpe A, Guarch R, Cortés JM, Pulido R, Llarena R, Angulo JC. CD34 immunostaining enhances a distinct pattern of intratumor angiogenesis with prognostic implications in clear cell renal cell carcinoma. APMIS. 2017 Feb;125(2):128-133. doi: 10.1111/apm.12649. — View Citation

McElreath, R. Statistical rethinking: A Bayesian course with examples in R and Stan. (CRC press, 2020).

Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005 Feb 1;23(4):832-41. — View Citation

Metropolis, N., Rosenbluth, A. W., Rosenbluth, M. N., Teller, A. H. & Teller, E. Equation of State Calculations by Fast Computing Machines. J. Chem. Phys. 21, 1087-1092 (1953).

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):115-24. — View Citation

Oudijk L, van Nederveen F, Badoual C, Tissier F, Tischler AS, Smid M, Gaal J, Lepoutre-Lussey C, Gimenez-Roqueplo AP, Dinjens WN, Korpershoek E, de Krijger R, Favier J. Vascular pattern analysis for the prediction of clinical behaviour in pheochromocytomas and paragangliomas. PLoS One. 2015 Mar 20;10(3):e0121361. doi: 10.1371/journal.pone.0121361. eCollection 2015. — View Citation

Paoluzzi L, Maki RG. Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review. JAMA Oncol. 2019 Feb 1;5(2):254-260. doi: 10.1001/jamaoncol.2018.4490. Review. — View Citation

Papaspiliopoulos, O., Roberts, G. O. & Sköld, M. A general framework for the parametrization of hierarchical models. Stat. Sci. 22, 59-73 (2007).

Pearl, J. Causality. (Cambridge university press, 2009).

Perkovic, E., Textor, J., Kalisch, M. & Maathuis, M. H. A complete generalized adjustment criterion. arXiv Prepr. arXiv1507.01524 (2015).

R Core Team. R: A Language and Environment for Statistical Computing. (2019)

Renne SL, Woo HY, Allegra S, Rudini N, Yano H, Donadon M, Viganò L, Akiba J, Lee HS, Rhee H, Park YN, Roncalli M, Di Tommaso L. Vessels Encapsulating Tumor Clusters (VETC) Is a Powerful Predictor of Aggressive Hepatocellular Carcinoma. Hepatology. 2020 Jan;71(1):183-195. doi: 10.1002/hep.30814. Epub 2019 Aug 9. — View Citation

Rubin, D. B. Inference and missing data. Biometrika 63, 581-592 (1976).

Setsu N, Yoshida A, Takahashi F, Chuman H, Kushima R. Histological analysis suggests an invasion-independent metastatic mechanism in alveolar soft part sarcoma. Hum Pathol. 2014 Jan;45(1):137-42. doi: 10.1016/j.humpath.2013.07.045. — View Citation

Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010 Feb 20;28(6):1061-8. doi: 10.1200/JCO.2009.23.9764. Epub 2010 Jan 25. — View Citation

Sugino T, Yamaguchi T, Hoshi N, Kusakabe T, Ogura G, Goodison S, Suzuki T. Sinusoidal tumor angiogenesis is a key component in hepatocellular carcinoma metastasis. Clin Exp Metastasis. 2008;25(7):835-41. doi: 10.1007/s10585-008-9199-6. Epub 2008 Aug 20. — View Citation

van der Zander, B., Liskiewicz, M. & Textor, J. Constructing Separators and Adjustment Sets in Ancestral Graphs. in Proceedings of UAI 11-24 (2014).

Watanabe, S. Asymptotic equivalence of Bayes cross validation and widely applicable information criterion in singular learning theory. J. Mach. Learn. Res. 11, 3571-3594 (2010).

* Note: There are 36 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	VETC in RCC and AC.	To identify the expression of VETC in Renal Cell Carcinoma and Adrenal Carcinoma.	2-3 months
Secondary	Predictive VETC (OS)	Treatment specific Overall Survival	2-3 months
Secondary	Predictive VETC (PFS)	Treatment specific Progression Free Survival	2-3 months
Secondary	Predictive VETC (control)	Treatment specific Disease Control Rate	2-3 months